Identifying children at risk for polycystic ovary syndrome

被引:198
作者
Rosenfield, Robert L.
机构
[1] Univ Chicago, Pritzker Sch Med, Dept Pediat, Sect Pediat Endocrinol,Comer Childrens Hosp, Chicago, IL 60637 USA
[2] Univ Chicago, Pritzker Sch Med, Dept Med, Sect Pediat Endocrinol,Comer Childrens Hosp, Chicago, IL 60637 USA
关键词
D O I
10.1210/jc.2006-2012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Polycystic ovary syndrome (PCOS) appears to arise as a complex trait with contributions from both heritable and nonheritable factors. Polygenic influences appear to account for about 70% of the variance in pathogenesis. In view of this evidence for congenital contributions to the syndrome, childhood manifestations may be expected. Objective: The objective has been to review the evidence that risk factors for PCOS can be recognized in childhood. Design: This study consisted of screening of the PCOS literature for articles pertaining to potential childhood and adolescent antecedents. Results: Congenital virilizing disorders; above average or low birth weight for gestational age; premature adrenarche, particularly exaggerated adrenarche; atypical sexual precocity; or intractable obesity with acanthosis nigricans, metabolic syndrome, and pseudo-Cushing syndrome or pseudo-acromegaly in early childhood have been identified as independent prepubertal risk factors for the development of PCOS. During adolescence, PCOS may masquerade as physiological adolescent anovulation. Asymptomatic adolescents with a polycystic ovary occasionally (8%) have subclinical PCOS but often (42%) have a subclinical PCOS type of ovarian dysfunction, the prognosis for which is unclear. Conclusion: Identifying children at risk for PCOS offers the prospect of eventually preventing some of the long-term complications associated with this syndrome once our understanding of the basis of the disorder improves.
引用
收藏
页码:787 / 796
页数:10
相关论文
共 120 条
[1]   Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? [J].
Abbott, DH ;
Barnett, DK ;
Bruns, CM ;
Dumesic, DA .
HUMAN REPRODUCTION UPDATE, 2005, 11 (04) :357-374
[2]  
ADAMS J, 1985, LANCET, V2, P1375
[3]   INSULIN RESISTANCE OF PUBERTY - A DEFECT RESTRICTED TO PERIPHERAL GLUCOSE-METABOLISM [J].
AMIEL, SA ;
CAPRIO, S ;
SHERWIN, RS ;
PLEWE, G ;
HAYMOND, MW ;
TAMBORLANE, WV .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 72 (02) :277-282
[4]   SERUM PREGNENOLONE, PROGESTERONE, 17-HYDROXYPROGESTERONE, TESTOSTERONE AND 5 ALPHA-DIHYDROTESTOSTERONE DURING FEMALE PUBERTY [J].
APTER, D ;
VIHKO, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1977, 45 (05) :1039-1048
[5]   Adrenarche - physiology, biochemistry and human disease [J].
Auchus, RJ ;
Rainey, WE .
CLINICAL ENDOCRINOLOGY, 2004, 60 (03) :288-296
[6]   Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline [J].
Azziz, Ricardo ;
Carmina, Enrico ;
Dewailly, Didier ;
Diamanti-Kandarakis, Evanthia ;
Escobar-Morreale, Hector F. ;
Futterweit, Walter ;
Janssen, Onno E. ;
Legro, Richard S. ;
Norman, Robert J. ;
Taylor, Ann E. ;
Witchel, Selma F. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (11) :4237-4245
[7]   Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity [J].
Baillargeon, JP ;
Jakubowicz, DJ ;
Iuorno, MJ ;
Jakubowicz, S ;
Nestler, JE .
FERTILITY AND STERILITY, 2004, 82 (04) :893-902
[8]   Obesity and polycystic ovary syndrome [J].
Barber, T. M. ;
McCarthy, M. I. ;
Wass, J. A. H. ;
Franks, S. .
CLINICAL ENDOCRINOLOGY, 2006, 65 (02) :137-145
[9]   Metformin for the treatment of polycystic ovary syndrome [J].
Barbieri, RL .
OBSTETRICS AND GYNECOLOGY, 2003, 101 (04) :785-793
[10]   Fetal origins of adult disease:: strength of effects and biological basis [J].
Barker, DJP ;
Eriksson, JG ;
Forsén, T ;
Osmond, C .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2002, 31 (06) :1235-1239